Allison Berger

Allison Berger

UNVERIFIED PROFILE

Are you Allison Berger?   Register this Author

Register author
Allison Berger

Allison Berger

Publications by authors named "Allison Berger"

Are you Allison Berger?   Register this Author

30Publications

944Reads

28Profile Views

Catalytically Active Peptide-Gold Nanoparticle Conjugates: Prospecting for Artificial Enzymes.

Angew Chem Int Ed Engl 2020 Jan 6. Epub 2020 Jan 6.

Freie Universität Berlin, Department of Chemistry and Biochemistry, Takustrasse 3, 14195, Berlin, GERMANY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/anie.201908625DOI Listing
January 2020

Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells.

Leuk Lymphoma 2019 Dec 21;60(12):2946-2950. Epub 2019 May 21.

Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1616190DOI Listing
December 2019

Deciphering the Fluorine Code-The Many Hats Fluorine Wears in a Protein Environment.

Acc Chem Res 2017 09 12;50(9):2093-2103. Epub 2017 Aug 12.

Institute of Chemistry and Biochemistry - Organic Chemistry, Freie Universität Berlin , Takustrasse 3, 14195 Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.accounts.7b00226DOI Listing
September 2017

The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.

Blood 2016 05 5;127(18):2219-30. Epub 2016 Feb 5.

Division of Hematology and Oncology, Department of Medicine, Virginia Commonwealth University and the Massey Cancer Center, Richmond, VA; Department of Biochemistry, Virginia Commonwealth University and the Massey Cancer Center and the Virginia Institute of Molecular Medicine, Richmond, VA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-06-653717DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859196PMC
May 2016

Fluorine teams up with water to restore inhibitor activity to mutant BPTI.

Chem Sci 2015 Sep 12;6(9):5246-5254. Epub 2015 Jun 12.

Department of Biology, Chemistry, and Pharmacy , Freie Universität Berlin , Institute of Chemistry and Biochemistry , Takustr. 3 , Berlin, 14195 , Germany . Email: ; ; Tel: +49-30-83855344.

View Article

Download full-text PDF

Source
http://xlink.rsc.org/?DOI=C4SC03227F
Publisher Site
http://dx.doi.org/10.1039/c4sc03227fDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669249PMC
September 2015

Targeting neddylation effectively antagonizes nuclear factor-κB in chronic lymphocytic leukemia B-cells.

Leuk Lymphoma 2015 May;56(5):1566-9

Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center , Lebanon, NH , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.990901DOI Listing
May 2015

Regulation of T cell receptor complex-mediated signaling by ubiquitin and ubiquitin-like modifications.

Am J Clin Exp Immunol 2014 5;3(3):107-23. Epub 2014 Dec 5.

Department of Pediatrics, University of Colorado School of Medicine Aurora, CO 80045, USA ; Integrated Department of Immunology, University of Colorado School of Medicine and National Jewish Health Denver, CO 80206, USA ; Division of Rheumatology, Colorado Children's Hospital Aurora, CO 80045, USA ; Since completing this study, Dr. Dragone has joined Genentech, a member of the Roche group. Genentech South San Francisco, CA 94090, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4299764PMC
January 2015

The discovery of a reciprocal relationship between tyrosine-kinase signaling and cullin neddylation.

PLoS One 2013 4;8(10):e75200. Epub 2013 Oct 4.

Department of Pediatrics, University of Colorado School of Medicine, Denver, Colorado, United States of America ; Integrated Department of Immunology, University of Colorado School of Medicine and National Jewish Health, Denver, Colorado, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0075200PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790728PMC
July 2014

Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.

Clin Cancer Res 2014 Mar 31;20(6):1542-54. Epub 2014 Jan 31.

Authors' Affiliations: Centro de Investigación del Cáncer, IBMCC (Universidad de Salamanca-CSIC); Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León; Hospital Universitario de Salamanca-IBSAL, Salamanca; Laboratorio de Imagen del Cáncer, Centro de Investigación Médica Aplicada, Universidad de Navarra, Pamplona, Spain; MGH Cancer Center, Massachusetts General Hospital; Dana-Farber Cancer Institute, Harvard Medical School, Boston; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA; and Departments of Cell Biology and Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1657DOI Listing
March 2014

Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924.

Mol Cancer Ther 2013 Oct 12;12(10):1958-67. Epub 2013 Aug 12.

Corresponding Author: Amir A. Jazaeri, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of Virginia Health System, Box 800712, Charlottesville, VA 22908.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-12-1028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795967PMC
October 2013

Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer.

Clin Cancer Res 2013 Jul 30;19(13):3577-90. Epub 2013 Apr 30.

Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-3212DOI Listing
July 2013

Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells.

Blood 2012 Nov 14;120(19):3958-67. Epub 2012 Sep 14.

LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2012-01-40
Publisher Site
http://dx.doi.org/10.1182/blood-2012-01-401794DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496955PMC
November 2012

A conserved RpoS-dependent small RNA controls the synthesis of major porin OmpD.

Nucleic Acids Res 2012 Apr 17;40(8):3623-40. Epub 2011 Dec 17.

RNA Biology Group, Institute for Molecular Infection Biology, University of Würzburg, Josef-Schneider-Strasse 2, D-97080 Würzburg, Germany.

View Article

Download full-text PDF

Source
https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/
Publisher Site
http://dx.doi.org/10.1093/nar/gkr1156DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3333887PMC
April 2012